Specialized Medical Mycology Center, Postgraduate Program in Medical Microbiology, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Antimicrob Agents Chemother. 2010 Sep;54(9):3978-9. doi: 10.1128/AAC.00793-10. Epub 2010 Jun 21.
This study evaluated the in vitro effect of sulfamethoxazole-trimethoprim against Histoplasma capsulatum var. capsulatum isolated from HIV-positive patients. The drugs were tested by microdilution testing in accordance with the CLSI guidelines. All of the strains were inhibited by sulfamethoxazole-trimethoprim, with MIC ranges of 0.039 (sulfamethoxazole)/0.0078 (trimethoprim) mg/ml to 0.625/0.125 mg/ml for mycelial forms and 0.0025/0.0005 to 0.02/0.004 mg/ml for yeast-like forms. However, in vivo studies are necessary to evaluate the significance of these results.
本研究评估了磺胺甲恶唑-甲氧苄啶对分离自 HIV 阳性患者的荚膜组织胞浆菌的体外作用。根据 CLSI 指南，采用微量稀释法进行药物测试。所有菌株均被磺胺甲恶唑-甲氧苄啶抑制，其菌丝体 MIC 范围为 0.039（磺胺甲恶唑）/0.0078（甲氧苄啶）mg/ml 至 0.625/0.125mg/ml，酵母样形式为 0.0025/0.0005 至 0.02/0.004mg/ml。然而，需要进行体内研究来评估这些结果的意义。
